Bayer more stringent in glyphosate settlement talks due to downturn

This post was originally published on this site

https://i-invdn-com.akamaized.net/news/fa8a2f803ea2ddf92359d55091dcde0a_M.jpg

The pandemic has significantly slowed the mediation process, it said in a statement on Monday.

“The company will consider a deal only if it is financially reasonable and puts in place a mechanism to resolve potential future claims efficiently. Against the background of a looming recession and looking at, in part, considerable liquidity challenges, this applies now more than ever,” Chief Executive Werner Baumann said.

The company added that fourth-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 10.2% to 4.39 billion euros ($4.76 billion), beating average analyst expectations of 4.17 billion, according to Refinitiv data.